Vascular Malformations

Background

Vascular anomalies are broadly divided into vascular tumors (proliferative lesions) and vascular malformations (structural lesions due to dysmorphogenesis). Malformations are typically present at birth, grow proportionally with the patient, and do not involute spontaneously. ^{[1] [2]}

ISSVA framework (clinical utility)

The ISSVA classification organizes vascular malformations by predominant vessel type and flow physiology, which directly informs imaging strategy and treatment selection. ^{[2] [3]}

Epidemiology and burden

• Vascular malformations are relatively common congenital lesions encountered across age groups and anatomic sites; many remain undiagnosed until growth, trauma, hormonal change, or thrombosis triggers symptoms. ^{[2] [8]}
• AVMs can behave aggressively with progression to pain, tissue destruction, ulceration, hemorrhage, ischemia, or high-output cardiac failure in large shunts. ^{[6] [9]}

Clinical pearl

• Flow classification is the first decision point: slow-flow lesions are generally managed with sclerotherapy-based strategies, while fast-flow AVMs require angiographic definition and nidus eradication strategies to reduce recurrence. ^{[9] [10]}

Etiology

• Embryologic developmental errors in angiogenesis and vasculogenesis during fetal development result in abnormal vascular connections and structural malformations.\n *Genetic and molecular causes:**\n + Somatic activating variants in the RAS/MAPK pathway (e.g., KRAS, MAP2K1) are implicated in many sporadic AVMs; MAP2K1 is well described in extracranial AVMs.\n + Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu syndrome): autosomal dominant pathogenic variants in ENG, ACVRL1, or SMAD4. Genetic testing and family screening should be considered in suspected cases.\n + Parkes Weber syndrome/CM-AVM: germline RASA1 variants associated with fast-flow limb overgrowth and AVMs. ^{[11] [12] [13] [14]}

Pathophysiology

• AVMs: direct arterial–venous connections bypassing the capillary bed.\n + Leads to low-resistance, high-flow shunt.\n + Results in venous hypertension, tissue ischemia, and progressive enlargement.\n *Venous malformations: ectatic, dysplastic venous channels with sluggish flow, thrombosis, and phleboliths.\n* Lymphatic malformations: abnormal lymphatic channels or cystic spaces, prone to infection and leakage.\n* Combined malformations: (e.g., capillary-venous, capillary-lymphatic-venous).\n* Systemic effects:** large AVMs → increased cardiac output demand → eventual high-output heart failure. ^{[2] [9] [15]}

Clinical Presentation

• Cutaneous lesions: swelling, skin discoloration, warmth, pulsatility (AVMs).\n *Symptoms: pain, functional impairment, bleeding, ulceration.\n* AVMs: bruit, thrill, distal ischemia, cardiac failure in large shunts.\n* Venous malformations: soft, compressible masses, worse with dependency, associated with 12VTE-like symptoms.\n* Lymphatic malformations: cystic, fluctuant, recurrent infection/lymphorrhea.\n* Complications:** ulceration, infection, skeletal overgrowth, disfigurement. ^{[4] [16]}\n\n<!-- type: classification -->\nSchobinger clinical staging (for AVMs): Stage I (quiescent) – warmth and cutaneous blush; Stage II (expansion) – enlargement, pulsation, bruit and thrill; Stage III (destruction) – pain, ulceration/bleeding, infection, ischemia; Stage IV (decompensation) – high-output cardiac failure. Staging helps time interventions and anticipate complications. ^[6]

Diagnostics

Diagnostic goals

1. Confirm slow-flow vs fast-flow physiology. ^[2]
2. Define extent (skin, subcutis, muscle, bone, viscera) and relationship to critical structures. ^{[8] [9]}
3. Identify treatable targets (venous lakes, lymphatic cysts, AVM nidus, dominant feeders/drainers). ^[9]

Initial evaluation

• History: congenital onset, growth triggers (puberty/pregnancy/trauma), bleeding, ulceration, infections, thrombosis-like pain episodes (venous malformations). ^[4]
• Exam: compressibility and dependency-related enlargement (venous), bruit/thrill/warmth (AVM), skin changes, limb overgrowth, distal ischemia. ^{[6] [2]}

Imaging workflow (practical approach)

1. Duplex ultrasound (DUS) as first-line to screen and classify flow.

1. MRI with contrast (including time-resolved MRA where available) is preferred for anatomic mapping and flow characterization, especially in complex/extensive lesions and pre-intervention planning. ^{[9] [17]}

1. CTA can complement MRI when assessing bone involvement, calcified phleboliths, or when MRI is limited/unavailable. ^[8]

1. Digital subtraction angiography (DSA) is reserved for fast-flow lesions when planning therapy; it defines the nidus, feeders, outflow, and guides staged embolization. ^{[9] [18]}

Modality selection table

Genetic testing (when to consider)

• Test when phenotype suggests syndromic disease (e.g., HHT, CM-AVM/Parkes Weber) because results drive screening of patient and relatives. ^{[13] [14]}
• Somatic variants (e.g., RAS/MAPK pathway) are increasingly recognized in sporadic AVMs and may influence referral to specialized anomaly programs. ^{[11] [12]}

General Principles

• Multidisciplinary care (vascular surgeon, interventional radiologist, dermatologist, plastic surgeon).\n *Goals: symptom control, prevent complications, preserve function.\n* Complete cure is rare** for AVMs; staged and repeated interventions are common. ^{[2] [6]}

Endovascular Therapy

Principles (apply to all endovascular therapy)

• Endovascular intervention is lesion- and flow-specific; misclassification (treating an AVM like a venous malformation) increases complications and recurrence. ^{[2] [9]}
• Staged treatment is common to reduce tissue necrosis, systemic toxicity, and post-procedure swelling/compartment risk. ^{[9] [7]}

1) AVM embolization (fast-flow lesions)

Indications

• Pain, ulceration, bleeding, functional impairment, progressive enlargement/destruction (Schobinger II–IV), or high-output physiology. ^[6]

Technical target

• The treatment target is the nidus (and/or direct arteriovenous shunt). Proximal feeder occlusion alone commonly results in collateral recruitment and recurrence and should be considered flow-control rather than definitive therapy. ^{[6] [7]}

Access routes

• Transarterial, transvenous (selected cases), and/or direct percutaneous nidus puncture depending on angioarchitecture and accessibility. ^[9]

Embolic agents (clinical positioning)

2) Sclerotherapy (slow-flow malformations)

• Venous malformations: image-guided sclerotherapy (US/fluoro) is first-line for symptomatic lesions, often requiring multiple sessions; symptom improvement is common, with generally low major complication rates in modern series and meta-analysis. ^{[5] [4]}
• Lymphatic malformations: macrocystic components are commonly treated with percutaneous sclerotherapy (agent choice and dosing depend on anatomy and institutional expertise). ^[9]

Common sclerosants used in practice

• Polidocanol, sodium tetradecyl sulfate (STS), doxycycline, bleomycin (agent selection depends on lesion characteristics and location). ^[5]

3) Combined strategies

• For resectable AVMs, embolization followed by surgery (often within days) can reduce blood loss and improve the chance of complete nidus removal. ^{[6] [10]}
• For extensive venous malformations, staged sclerotherapy plus limited debulking can improve function/cosmesis while acknowledging recurrence risk. ^{[4] [16]}

Complications and risk mitigation

• Skin necrosis, nerve injury, deep venous thrombosis, non-target embolization, bleeding, infection, and post-embolization swelling. Prevention includes careful staging, image guidance, and multidisciplinary peri-procedural planning. ^{[9] [7]}

Surgical Therapy

Role of surgery

Surgery is best suited to localized, well-demarcated malformations where complete treatment targets can be removed or definitively controlled. For AVMs, the operative goal is complete nidus excision when feasible; incomplete resection or feeder ligation without nidus control is associated with recurrence/progression. ^{[6] [10]}

Indications

• Localized AVM amenable to complete excision (often Schobinger II–III). ^[6]
• Symptomatic venous malformation requiring debulking after sclerotherapy to improve function/cosmesis. ^{[4] [16]}
• Complications requiring operative management: nonhealing ulceration, recurrent bleeding, infection/necrosis, or functional compromise. ^[16]

Pre-operative planning

• MRI defines extent and tissue planes; DSA findings (for AVMs) guide what must be controlled/excised. ^{[9] [18]}
• Pre-operative embolization for AVMs can reduce blood loss and facilitate dissection; timing is typically coordinated closely with surgery to prevent interval collateralization. ^{[6] [10]}

Expected outcomes and limitations

• Localized lesions: best chance for durable control when complete excision is achieved. ^[6]
• Diffuse/infiltrative AVMs: “curative” resection is uncommon; operations are often debulking/palliation after flow reduction, with an expectation of recurrence and need for longitudinal care. ^{[6] [9]}

Systemic and Adjunctive Therapies

Targeted/medical therapy

• mTOR inhibition (sirolimus): used in selected patients with complex, symptomatic vascular malformations (particularly lymphatic and combined malformations) when morbidity is high and procedural options are limited or insufficient; requires specialist oversight and monitoring for immunosuppression-related adverse effects. ^{[19] [2]}

Adjunctive local therapy

• Laser therapy: useful for superficial capillary malformations (e.g., port-wine stains) and select superficial components as part of multidisciplinary care. ^[2]
• Compression therapy: often beneficial for symptomatic venous malformations to reduce pain and swelling (adjunct to sclerotherapy/surgery). ^[4]

Anticoagulation / antithrombotic therapy

• Venous malformations can be associated with thrombosis-like pain episodes and thrombotic complications; anticoagulation decisions should follow contemporary VTE risk/benefit principles and be individualized (see 12VTE). ^{[4] [20] [21]}

Follow-up

Longitudinal care model

Vascular malformations are chronic conditions; recurrence/progression and staged re-intervention are common, especially for AVMs and extensive combined malformations. Follow-up should be coordinated through a multidisciplinary vascular anomaly team. ^{[2] [9]}

Suggested surveillance (typical practice pattern)

• Clinical review after each procedure (2–6 weeks) to assess wound/skin integrity, neurologic status, pain control, and function. ^[9]
• Imaging (tailored to lesion type):

• Venous/lymphatic malformations: DUS as needed for symptomatic changes; MRI for interval mapping when progression is suspected or for procedural planning. ^[9]
• AVMs: MRI for extent and soft-tissue effects; DSA is reserved for planned re-intervention. ^{[9] [18]}

Supportive care

• Pain management, physiotherapy/occupational therapy, and compression (for venous malformations) as indicated. ^[4]
• Genetic counseling and family screening when heritable syndromes are suspected/confirmed (e.g., HHT, CM-AVM). ^{[13] [14]}

Guidelines and Consensus

Consensus-driven foundations for care

• Use standardized terminology and classify lesions by ISSVA to align imaging, outcomes reporting, and treatment selection. ^{[2] [3]}
• Establish flow status early (slow vs fast) to guide first-line therapy (sclerotherapy-based vs nidus-directed embolization). ^{[2] [9]}
• Favor multidisciplinary evaluation (vascular surgery, interventional radiology, dermatology, plastic surgery, genetics) for complex lesions and syndromic presentations. ^[2]

Disease-specific guideline example (HHT)

• The Second International HHT Guidelines recommend screening strategies and support transcatheter embolization as first-line therapy for pulmonary AVMs meeting treatment criteria, and they emphasize family evaluation when a pathogenic variant is identified. ^[13]

Schobinger clinical staging of AVMs

\nThe Schobinger staging system for AVMs classifies disease progression into four stages based on clinical presentation:\n\n *Stage I (Quiescent): warmth and cutaneous blush or pink-blue discoloration.\n* Stage II (Expansion): enlargement with pulsation, bruit, and thrill.\n* Stage III (Destruction): pain, ulceration or bleeding, infection, and tissue ischemia.\n* Stage IV (Decompensation):** high-output cardiac failure. ^[6]\n\nTreatment urgency increases with advancing stage. Stage IV disease often requires aggressive flow reduction prior to any resection to stabilize cardiac function. ^[6]

Hereditary hemorrhagic telangiectasia (HHT) and pulmonary AVMs

In patients with hereditary hemorrhagic telangiectasia (HHT), screening for pulmonary arteriovenous malformations (PAVMs) is performed using contrast echocardiography in adults and at-risk relatives. Positive screening studies are confirmed with chest CT. Transcatheter coil or plug embolization represents first-line treatment for PAVMs meeting criteria for intervention. Genetic testing for pathogenic variants in ENG, ACVRL1, or SMAD4 should be offered to confirm the diagnosis, and family counseling should address screening recommendations for first-degree relatives. ^[13]

Evidence summary for sclerotherapy and embolization outcomes/complications

What outcomes to expect (practical framing)

• AVM embolization: durable control depends on nidus-directed therapy; staged sessions are common. Ethanol can be effective in experienced centers but carries higher complication risk and requires meticulous technique and monitoring. ^{[7] [9]}
• Slow-flow malformations: sclerotherapy provides symptom improvement for many patients; multiple sessions are often required, and agent selection should be individualized by lesion morphology and anatomic risk. ^{[5] [4]}

Agent comparison (high-yield)